Generex Biotechnology Corporation - Product Pipeline Review - 2015

Date: December 23, 2015
Pages: 30
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G63F76C0112EN
Leaflet:

Download PDF Leaflet

Generex Biotechnology Corporation - Product Pipeline Review - 2015

SUMMARY

Global Markets Direct’s, ‘Generex Biotechnology Corporation - Product Pipeline Review - 2015’, provides an overview of the Generex Biotechnology Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Generex Biotechnology Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides brief overview of Generex Biotechnology Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Generex Biotechnology Corporation’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Generex Biotechnology Corporation’s pipeline products
REASONS TO BUY
  • Evaluate Generex Biotechnology Corporation’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Generex Biotechnology Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Generex Biotechnology Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Generex Biotechnology Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Generex Biotechnology Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Generex Biotechnology Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Generex Biotechnology Corporation Snapshot
Generex Biotechnology Corporation Overview
Key Information
Key Facts
Generex Biotechnology Corporation - Research and Development Overview
Key Therapeutic Areas
Generex Biotechnology Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Generex Biotechnology Corporation - Pipeline Products Glance
Generex Biotechnology Corporation - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Generex Biotechnology Corporation - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Generex Biotechnology Corporation - Drug Profiles
insulin human
Product Description
Mechanism of Action
R&D Progress
AE-IG vaccine
Product Description
Mechanism of Action
R&D Progress
AE-O vaccine
Product Description
Mechanism of Action
R&D Progress
fentanyl citrate
Product Description
Mechanism of Action
R&D Progress
morphine sulfate
Product Description
Mechanism of Action
R&D Progress
Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis
Product Description
Mechanism of Action
R&D Progress
Generex Biotechnology Corporation - Pipeline Analysis
Generex Biotechnology Corporation - Pipeline Products by Target
Generex Biotechnology Corporation - Pipeline Products by Route of Administration
Generex Biotechnology Corporation - Pipeline Products by Molecule Type
Generex Biotechnology Corporation - Pipeline Products by Mechanism of Action
Generex Biotechnology Corporation - Recent Pipeline Updates
Generex Biotechnology Corporation - Dormant Projects
Generex Biotechnology Corporation - Company Statement
Generex Biotechnology Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Generex Biotechnology Corporation, Key Information
Generex Biotechnology Corporation, Key Facts
Generex Biotechnology Corporation - Pipeline by Indication, 2015
Generex Biotechnology Corporation - Pipeline by Stage of Development, 2015
Generex Biotechnology Corporation - Monotherapy Products in Pipeline, 2015
Generex Biotechnology Corporation - Phase III, 2015
Generex Biotechnology Corporation - Phase I, 2015
Generex Biotechnology Corporation - Pipeline by Target, 2015
Generex Biotechnology Corporation - Pipeline by Route of Administration, 2015
Generex Biotechnology Corporation - Pipeline by Molecule Type, 2015
Generex Biotechnology Corporation - Pipeline Products by Mechanism of Action, 2015
Generex Biotechnology Corporation - Recent Pipeline Updates, 2015
Generex Biotechnology Corporation - Dormant Developmental Projects,2015
Generex Biotechnology Corporation, Subsidiaries

LIST OF FIGURES

Generex Biotechnology Corporation - Pipeline by Top 10 Indication, 2015
Generex Biotechnology Corporation - Pipeline by Stage of Development, 2015
Generex Biotechnology Corporation - Monotherapy Products in Pipeline, 2015
Generex Biotechnology Corporation - Pipeline by Top 10 Target, 2015
Generex Biotechnology Corporation - Pipeline by Top 10 Route of Administration, 2015
Generex Biotechnology Corporation - Pipeline by Top 10 Molecule Type, 2015
Generex Biotechnology Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Ask Your Question

Generex Biotechnology Corporation - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: